RxDoctor Payments DataLook up a doctor →

John Rubino, MD

Internal Medicine · Raleigh, NCNPI 1962543280

Payments from drug & device makers

$13,037,781in general payments, 2019–2025

Across 2,037 payments — averaging $6400.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4.3M
  • Bavarian Nordic A/s$1.5M
  • Eli Lilly$1.3M
  • Biontech SE$1.2M
  • Modernatx, Inc.$1.1M
  • Regeneron$914K
  • plus $2.7M from 51 others
$72,649in research payments, 2019–2025

Across 19 payments — averaging $3823.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$66K
  • Pfizer$5K
  • Regeneron$2K

What the payments were for

  • Consulting fees$5,84145%
  • Travel & lodging$2,61620%
  • Food & beverage$4,55635%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer469$4,329,300
Bavarian Nordic A/s89$1,524,194
Eli Lilly15$1,257,344
Biontech SE213$1,202,515
Modernatx, Inc.82$1,138,307
Regeneron162$914,376
Johnson & Johnson(2 entities)34$895,739
AbbVie(2 entities)118$278,991
Novo Nordisk AS34$213,967
Hoffmann-la Roche Limited11$144,424
GSK40$126,963
Biohaven Pharmaceuticals, Inc.14$111,277
GRT US Holding, Inc.36$104,808
Seqirus USA Inc221$102,429
Amgen(2 entities)35$100,894
Novartis20$97,374
Kowa Research Institute, Inc.34$83,148
H. Lundbeck A S29$80,820
Merck113$80,351
Esperion Therapeutics, Inc.105$70,224
Biohaven Pharmaceutical Holding Company Ltd.15$68,566
Boehringer Ingelheim11$35,608
BD4$23,523
Tolmar, Inc.6$21,486
Ferring International Pharmascience Center US4$11,784
Teva Pharmaceuticals USA, Inc.9$6,687
Ferring Pharmaceuticals AS3$5,403
Amarin Pharma, Inc.6$5,362
Novo Nordisk25$462
AstraZeneca20$327
Lilly USA, LLC8$128
Abbott4$101
Astellas Pharma US Inc5$96
Exact Sciences5$86
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$81
E.r. Squibb & Sons, L.L.C.3$58
Otsuka America Pharmaceutical, Inc.2$55
Eisai Inc.3$52
Daiichi Sankyo Inc.3$52
Medtronic2$39
Sanofi-aventis U.S. LLC2$36
Medline Industries LP1$33
Takeda Pharmaceuticals U.S.A., Inc.2$32
Gilead2$30
Sunovion Pharmaceuticals Inc.1$25
Bausch Health US, LLC1$24
Amneal Pharmaceuticals LLC2$24
Optinose US, Inc.1$23
Bayer1$20
Insulet Corporation1$19
Endo USA, Inc.1$19
Sumitomo Pharma America, Inc.1$18
Biogen1$17
Radius Health, Inc.1$17
Dexcom, Inc.1$16
Xeris Pharmaceuticals, Inc.1$14
Kowa Pharmaceuticals America, Inc.1$11

How this compares

$13,037,781 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$171,095
Medicare patients
206
Services billed
5,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab16$156,036
OzempicSemaglutide108$120,793
EliquisApixaban87$105,126
JardianceEmpagliflozin77$89,945
Repatha SureclickEvolocumab116$86,119
CreonLipase/Protease/Amylase22$49,459
JanuviaSitagliptin Phosphate35$39,544
MyrbetriqMirabegron42$36,463
MounjaroTirzepatide24$32,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$30,044
Emgality PenGalcanezumab-Gnlm24$28,024
TrulicityDulaglutide22$26,385
NexletolBempedoic Acid26$22,638
SynjardyEmpagliflozin/Metformin Hcl18$21,615
TradjentaLinagliptin12$18,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Tradjenta$35,608$130,130107 claims
Novo NordiskOzempic, Novolog Mix 70-30$462$124,207120 claims
PfizerEliquis$4,329,300$105,12687 claims
Lilly USA, LLCMounjaro, Trulicity$128$58,71746 claims
AbbVieCreon, Synthroid$278,991$57,083117 claims
MerckJanuvia, Janumet Xr$80,351$51,34854 claims
GSKTrelegy Ellipta, Breo Ellipta$126,963$38,54649 claims
Astellas Pharma US IncMyrbetriq$96$36,46342 claims
Esperion Therapeutics, Inc.Nexletol$70,224$22,63826 claims
AstraZenecaFarxiga$327$17,76914 claims
NovartisEntresto$97,374$13,43515 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$7,352528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →